supra-ABE (Adenine Base Editor)

Engineered adenine base editor for gene knockout and correction

The supra-ABE enzyme is a high-performance adenine base editor featuring exceptional editing efficiency, a broad activity window, and low off-target effects—making it a powerful tool for precise, targeted cell and gene therapy applications. It is built on a patented architecture where the novel eMa-TadA adenine deaminase is chimerically embedded within a Cas9 nickase (Cas9n) to enhance editing precision and flexibility.

Developed exclusively by Lumiere Therapeutics, supra-ABE was further optimized for commercial production by KACTUS using our SAMS™ platform (Structure-Aided design and Multiplex Screening) to ensure high purity, superior stability, and consistent editing performance. KACTUS is the exclusive provider of this advanced base editing enzyme.

View supra-ABE

How does supra-ABE base editor work?

Efficient A-to-G Conversion with Wide Editing Window

The engineered adenine deaminase eMa-TadA in supra-ABE catalyzes the conversion of adenine (A) to inosine (I) in DNA. During replication, inosine is interpreted as guanine (G), enabling precise A-to-G substitutions within positions 4–14 of the editing window. This process occurs without the need for donor templates or the induction of double-strand DNA breaks, minimizing genomic disruption.

View supra-ABE

Applications of supra-ABE base editor

Gene Knockout

Gene knockout can be achieved by introducing A-to-G or T-to-C substitutions that disrupt key genetic elements—such as mutating the start codon (ATG) or altering canonical splice sites (GT-AG)—effectively disabling gene function.

Gene Correction

The supra-ABE editor enables precise single-base correction of pathogenic mutations. By converting specific adenine or thymine bases to guanine or cytosine, it restores normal gene function without introducing double-strand breaks.

View supra-ABE

Gene knockout and gene correction applications of supra-ABE.

Product Performance Data

High Base Editing Activity Verus ABE8e

Sanger sequencing and EditR analysis demonstrate that supra-ABE efficiently mediates A-to-G conversion in the start codon (ATG) of PD1 and CD3G genes, disrupting translation initiation and achieving approximately 90% knockout efficiency.

Wide Editing Window

Sanger sequencing and EditR analysis results show that supra-ABE can convert A to G within the editing window, with varying editing efficiencies for adenine (A) bases at different positions—the highest editing efficiency exceeds 90%. Additionally, the editing window of supra-ABE is wider than that of ABE8e.

Efficient Knockout of CD3G Protein

FACS analysis demonstrated that supra-ABE efficiently knocked out the CD3G protein, achieving a knockout efficiency of 90.21%.

Greater than 95% Purity

SEC-HPLC analysis confirms supra-ABE purity exceeds 95.0%.

Bis-Tris PAGE analysis confirms supra-ABE purity exceeds 95.0%.

View supra-ABE

Advantages of supra-ABE

Proprietary Intellectual Property

Supra-ABE is a commercial-grade adenine base editor developed under an independent patent, ensuring freedom to operate and strong intellectual property protection.

High Editing Efficiency

Engineered for robust performance, supra-ABE enables efficient editing across a wide range of gene loci, supporting high-throughput target screening.

Broad Editing Window

With an expanded editing window (positions 4–14), supra-ABE outperforms traditional ABE8e, offering greater flexibility in target site selection.

Flexible Targeting Abilities

Ideal for gene therapy, cell therapy, and epigenetic applications, supra-ABE enables efficient editing of key regulatory elements—such as start codons (ATG) and splice sites (GT-AG)—supporting gene knockout, exon skipping, and more.